Efficacy and Safety of Suvratoxumab for Prevention of S. aureus Ventilator–Associated Pneumonia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Infectious Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial
Lancet Infect Dis 2021 Sep 01;21(9)1313-1323, B François, HS Jafri, J Chastre, M Sánchez-García, P Eggimann, PF Dequin, V Huberlant, L Viña Soria, T Boulain, C Bretonnière, J Pugin, J Trenado, AC Hernandez Padilla, O Ali, K Shoemaker, P Ren, FE Coenjaerts, A Ruzin, O Barraud, L Timbermont, C Lammens, V Pierre, Y Wu, J Vignaud, S Colbert, T Bellamy, MT Esser, F Dubovsky, MJ Bonten, H Goossens, PF LaterreFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.